Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Risks of Different Testosterone Preparations

Risks of Different Testosterone Preparations Comparative Safety of Testosterone Dosage Forms Original Investigation Research Invited Commentary Too Much, Too Little, Just Right Margaret E. Wierman, MD There is a developing story that the increased use of testos- United States are written without determination of a level and terone therapy without a diagnosis of hypogonadism is asso- that more than 30% of patients receiving testosterone therapy ciated with an elevated cardiovascular risk for some patients. do not have follow-up laboratory testing. Taken together, these In this issue of JAMA Inter- reports suggest that testosterone therapy is often being pre- nal Medicine,Laytonand scribed off label as an anabolic steroid and not for a diagnosis Related article page 1187 coauthors deepen our knowl- of hypogonadism, which requires signs and symptoms to- edge with their analysis of gether with a testosterone level below the reference range. 3 large databases (Truven MarketScan and Medicare cohorts The results from the analysis by Layton and coworkers are con- from the United States and the Clinical Practice Research sistent with most, but not all, recent epidemiologic data sets ; Datalink cohort from the United Kingdom) to ask whether they together, these studies can inform both patients and health care could detect a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Risks of Different Testosterone Preparations

JAMA Internal Medicine , Volume 175 (7) – Jul 1, 2015

Loading next page...
 
/lp/american-medical-association/risks-of-different-testosterone-preparations-hJLnIoO5QU
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2015.1580
pmid
25961437
Publisher site
See Article on Publisher Site

Abstract

Comparative Safety of Testosterone Dosage Forms Original Investigation Research Invited Commentary Too Much, Too Little, Just Right Margaret E. Wierman, MD There is a developing story that the increased use of testos- United States are written without determination of a level and terone therapy without a diagnosis of hypogonadism is asso- that more than 30% of patients receiving testosterone therapy ciated with an elevated cardiovascular risk for some patients. do not have follow-up laboratory testing. Taken together, these In this issue of JAMA Inter- reports suggest that testosterone therapy is often being pre- nal Medicine,Laytonand scribed off label as an anabolic steroid and not for a diagnosis Related article page 1187 coauthors deepen our knowl- of hypogonadism, which requires signs and symptoms to- edge with their analysis of gether with a testosterone level below the reference range. 3 large databases (Truven MarketScan and Medicare cohorts The results from the analysis by Layton and coworkers are con- from the United States and the Clinical Practice Research sistent with most, but not all, recent epidemiologic data sets ; Datalink cohort from the United Kingdom) to ask whether they together, these studies can inform both patients and health care could detect a

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jul 1, 2015

References